# Novavax and Healthcare Growth Stocks Drop as Treasury Yields Rise

- URL: https://stocks.freetheai.org/news/novavax-and-healthcare-growth-stocks-drop-as-treasury-yields-rise-6f4135
- Published: 2026-10-16T20:20:44Z
- Category: macro; sentiment: bearish; impact: medium
- Symbols: [NASDAQ:NVAX](https://stocks.freetheai.org/symbols/NASDAQ-NVAX), [NASDAQ:OCUL](https://stocks.freetheai.org/symbols/NASDAQ-OCUL), [NASDAQ:QDEL](https://stocks.freetheai.org/symbols/NASDAQ-QDEL)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of healthcare and biotechnology companies fell sharply during afternoon trading as climbing Treasury yields weighed on high-growth assets. Novavax, Inc. (NASDAQ:NVAX) dropped 12.17% to $11.26, while Ocular Therapeutix Inc (NASDAQ:OCUL) fell 6.91% to $6.87 and QuidelOrtho Corporation (NASDAQ:QDEL) declined 7.19% to $12.91.

Higher interest rates increase the discount rate applied to future corporate earnings, reducing the present value of expected cash flows. This pressure particularly impacts clinical-stage and capital-intensive healthcare firms, which depend on borrowing money to fund long-term research and development. Investors shifted funds away from higher-risk assets toward Treasury securities and blue-chip stocks.

Despite the daily decline, Novavax remains up 57.1% year-to-date, trading 12.6% below its 52-week high of $12.82 set in October 2026. The company's stock has experienced high volatility over the past year, including a 24.4% surge eight months ago following a fourth-quarter profit of $0.11 per share on revenue of $147.1 million. However, long-term returns reflect broader struggle, with a $1,000 investment from five years ago now valued at $67.37.

## Key points

- Novavax, Inc. (NASDAQ:NVAX) fell 12.17% to $11.26 as rising Treasury yields reduced market appetite for growth stocks.
- Ocular Therapeutix Inc (NASDAQ:OCUL) dropped 6.91% to $6.87, and QuidelOrtho Corporation (NASDAQ:QDEL) fell 7.19% to $12.91.
- Higher interest rates raise discount rates on future earnings, harming early-stage healthcare firms relying on debt financing.
- Novavax is up 57.1% year-to-date but remains 12.6% below its 52-week high of $12.82 set in October 2026.

## Questions and answers

### Why did Novavax stock fall?

Novavax stock fell as rising Treasury yields put pressure on capital-intensive healthcare growth equities. Higher interest rates lower the present value of future earnings and make debt financing for research and development more costly.

### How much did Novavax, Ocular Therapeutix, and QuidelOrtho drop?

Novavax dropped 12.17% to $11.26, Ocular Therapeutix fell 6.91% to $6.87, and QuidelOrtho declined 7.19% to $12.91 during afternoon trading.

### What is Novavax's 52-week high?

Novavax reached a 52-week high of $12.82 in October 2026. Despite recent losses, the stock remains up 57.1% year-to-date.